Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer
Journal of the National Comprehensive Cancer Network · 2025
DOI: 10.6004/jnccn.2025.7031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Robert W Lentz und 9 weiteren Autor:innen. Beteiligte Einrichtung: 1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The most used first-line chemotherapy backbone for metastatic colorectal cancer (mCRC) is fluoropyrimidine and oxaliplatin. Despite limited data supporting the superiority of second-line FOLFIRI over irinotecan, guidelines continue to endorse both options, and FOLFIRI remains more commonly used. Patients and Methods: This study used a nationwide electronic health record–derived deidentified database to select patients with mCRC who received first-line treatment with fluoropyrimidine and oxaliplatin with or without a biologic agent, and second-line treatment with irinotecan ± fluorouracil with or without a biologic agent. The Kaplan-Meier method was used to estimate survival outcomes, and the Cox proportional hazards model was used for univariable and multivariable analyses (MVA).
Results
A total of 3,215 patients met the eligibility criteria for inclusion in the analysis. In the second-line setting, FOLFIRI was the most commonly used chemotherapy backbone (90.6% vs 9.4% for irinotecan). Most patients also received a biologic agent, and those who received FOLFIRI were younger and had better ECOG performance status. There was no difference in first-line treatment duration or second-line irinotecan dose intensity between the FOLFIRI and irinotecan cohorts. Overall survival (OS) was longer with FOLFIRI than with irinotecan (median, 14.4 vs 9.8 months; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
- 2Department of Biostatistics and Bioinformatics, University of Colorado School of Medicine, Aurora, CO.
Förderung
- NCI NIH HHS
Zitieren
APA
Lentz, R. W., Hu, J., Robinson, H., Balmaceda, N., Baiyee, E., Leal, A. D., Kim, S. S., Davis, S. L., Messersmith, W. A., & Lieu, C. H. (2025). Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7031
Vancouver
Lentz RW, Hu J, Robinson H, Balmaceda N, Baiyee E, Leal AD, et al. Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2025.7031
BibTeX
@article{Lentz2025,
author = {Lentz, Robert W and Hu, Junxiao and Robinson, Hannah and Balmaceda, Nicole and Baiyee, Emily and Leal, Alexis D and Kim, Sunnie S and Davis, Sarah Lindsey and Messersmith, Wells A and Lieu, Christopher H},
title = {Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
doi = {10.6004/jnccn.2025.7031}
}
EUVIMED